Pharming Group N.V. (PHAR)
NASDAQ: PHAR · IEX Real-Time Price · USD
10.47
+0.58 (5.86%)
At close: Apr 25, 2024, 3:59 PM
10.45
-0.02 (-0.19%)
After-hours: Apr 25, 2024, 4:00 PM EDT
Pharming Group Stock Forecast
Stock Price Forecast
The 1 analyst with a 12-month price forecast for Pharming Group stock has a target of 37, which predicts an increase of 253.39% from the current stock price of 10.47.
Analyst Consensus: Strong Buy
* Price targets were last updated on Mar 14, 2024.
Analyst Ratings
According to 1 stock analyst, the rating for Pharming Group is "Strong Buy". This means that the analyst believes this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Nov '23 | Dec '23 | Jan '24 | Feb '24 | Mar '24 | Apr '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Buy | 1 | 1 | 1 | 1 | 1 | 0 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 2 | 2 | 2 | 2 | 2 | 1 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $37 | Strong Buy | Reiterates | $37 | +253.39% | Mar 14, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $37 | Strong Buy | Reiterates | $37 | +253.39% | Aug 3, 2023 |
| Oppenheimer | Oppenheimer | Buy Maintains $36 → $40 | Buy | Maintains | $36 → $40 | +282.04% | Mar 28, 2023 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $37 | Strong Buy | Reiterates | $37 | +253.39% | Mar 27, 2023 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $37 | Strong Buy | Reiterates | $37 | +253.39% | Feb 22, 2023 |
Financial Forecast
Revenue This Year
294.30M
from 245.32M
Increased by 19.97%
Revenue Next Year
337.48M
from 294.30M
Increased by 14.67%
EPS This Year
0.01
from -0.16
EPS Next Year
0.03
from 0.01
Increased by 245.45%
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|
| High | 304.7M | 356.9M | 421.9M | 448.5M |
| Avg | 294.3M | 337.5M | 387.1M | 424.1M |
| Low | 275.6M | 314.7M | 346.5M | 388.4M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|
| High | 24.2% | 21.3% | 25.0% | 15.9% |
| Avg | 20.0% | 14.7% | 14.7% | 9.5% |
| Low | 12.3% | 6.9% | 2.7% | 0.3% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|
| High | 0.03 | 0.06 | 0.10 | 0.14 |
| Avg | 0.01 | 0.03 | 0.07 | 0.14 |
| Low | -0.01 | -0.01 | 0.01 | 0.13 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|
| High | - | 641.4% | 232.7% | 109.6% |
| Avg | - | 245.5% | 124.6% | 105.6% |
| Low | - | - | -66.6% | 95.6% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.